PDS Biotechnology Corp. Stock News

New Patent Grants Broad Composition Claims for PDS0101 Previously Granted Patent Protections and Anticipated Market Exclusivity Provide Protection for PDS0101 in the United States into the 2040s PRINCETON, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immun...

Company to Discuss Proposed Amendment to Phase 3 VERSATILE-003 Trial Enabling Potential Accelerated Approval Pathway Company to Discuss Proposed Amendment to Phase 3 VERSATILE-003 Trial Enabling Potential Accelerated Approval Pathway

PDS Biotechnology Corporation ( PDSB ) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST Company Participants Frank Bedu-Addo - President, CEO & Director Lars Boesgaard - Principal Financial & Accounting Officer and CFO Kirk Shepard - Chief Medical Officer Conference Call Participants Thomas Johnson - Lifesci Advisors, LLC Mayank Mamtani - B. Riley Securities, Inc., Research Division Joseph P...

Company Announced Completion of VERSATILE-002 Phase 2 trial of PDS0101 + Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Cancer

PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that it has entered into a securities purchase agreement for the purchase and sale of 5,800,000 shares of common stock (or pre-funded warrants ...

Translational study shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapy  PDS01ADC reprograms natural killer (NK) cells to possess characteristics that make them more active in killing cancer cells PDS01ADC promotes stem cell-like killer T cells and memory T cells that self-replicate and are therefore capable of potent and long-lasting anti-t...

PRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call to report financial results for the quarter ended September 30, 2025 and provide a clinical progra...

Three abstracts accepted for presentation, including one rapid oral abstract session Presentations to highlight ongoing clinical and translational research across PDS Biotechnology's immunotherapy platforms PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming h...